Survival of contemporary patients with non-metastatic urachal vs. non-urachal adenocarcinoma of the urinary bladder.
Adenocarcinoma
Inverse probability of treatment weighting
Non-urachal
Propensity score
Urachal
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
03
09
2019
accepted:
06
01
2020
pubmed:
22
1
2020
medline:
22
6
2021
entrez:
22
1
2020
Statut:
ppublish
Résumé
To test the effect of tumor location (urachal vs. non-urachal) on cancer-specific mortality (CSM) in patients with adenocarcinoma of the urinary bladder (ADKUB). Within the Surveillance, Epidemiology, and End Results registry (2004-2016), we identified patients with non-metastatic (≤ T4N0M0) ADKUB. Stratification was made according to tumor location: urachal vs. non-urachal ADKUB. Kaplan-Meier plots and multivariable Cox regression models were fitted before and after 1:3 propensity score (PS) matching and separate Cox regression models were refitted before and after inverse probability of treatment weighting (IPTW). Of 1681 patients, 226 (13.5%) vs. 1455 (86.5%) harboured urachal vs. non-urachal ADKUB, respectively. Five-year cancer-specific survival (CSS) rates were, respectively, 75 vs. 67% for urachal vs. non-urachal ADKUB (p = 0.001). In subgroup analyses of ≤ T2N0M0 patients, 5-year CSS rates were, respectively, 84 vs. 73% for urachal vs. non-urachal ADKUB (p = 0.006). In subgroup analyses of T3-4N0M0 patients, 5-year CSS rates were, respectively, 68 vs. 49% for urachal vs. non-urachal ADKUB (p < 0.001). In multivariable Cox regression models, urachal ADKUB was associated with lower CSM rates (HR 0.6; p = 0.01). Virtually, the same findings were recorded after 1:3 PS matching (HR 0.6; p = 0.009) as well as when Cox regression models were refitted after IPTW (HR 0.7; p = 0.01). The distinction between urachal vs. non-urachal ADKUB indicates better prognosis when the origin of the tumor is urachal, regardless of methodological approach used for the comparison.
Identifiants
pubmed: 31960108
doi: 10.1007/s00345-020-03083-5
pii: 10.1007/s00345-020-03083-5
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2819-2826Commentaires et corrections
Type : CommentIn
Références
Moschini M, D’Andrea D, Korn S et al (2017) Characteristics and clinical significance of histological variants of bladder cancer. Nat Rev Urol 14:651
doi: 10.1038/nrurol.2017.125
Baumeister P, Zamboni S, Mattei A et al (2019) Histological variants in non-muscle invasive bladder cancer. Transl Androl Urol 8:34–38. https://doi.org/10.21037/tau.2019.01.09
doi: 10.21037/tau.2019.01.09
pubmed: 6414352
pmcid: 6414352
Manunta A, Vincendeau S, Kiriakou G et al (2005) Non-transitional cell bladder carcinomas. BJU Int 95:497–502. https://doi.org/10.1111/j.1464-410X.2005.05327.x
doi: 10.1111/j.1464-410X.2005.05327.x
pubmed: 15705067
pmcid: 15705067
Szarvas T, Módos O, Niedworok C et al (2016) Clinical, prognostic, and therapeutic aspects of urachal carcinoma—a comprehensive review with meta-analysis of 1010 cases. Urol Oncol Semin Orig Investig 34:388–398. https://doi.org/10.1016/j.urolonc.2016.04.012
doi: 10.1016/j.urolonc.2016.04.012
Siefker-Radtke A (2006) Urachal carcinoma: surgical and chemotherapeutic options. Expert Rev Anticancer Ther 6:1715–1721. https://doi.org/10.1586/14737140.6.12.1715
doi: 10.1586/14737140.6.12.1715
pubmed: 17181485
Flaig TW, Spiess PE, Agarwal N et al (2018) NCCN guidelines insights: bladder cancer, version 52018. J Natl Compr Cancer Netw. https://doi.org/10.6004/jnccn.2018.0072
doi: 10.6004/jnccn.2018.0072
Wright JL, Porter MP, Li CI et al (2006) Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder. Cancer 107:721–728. https://doi.org/10.1002/cncr.22059
doi: 10.1002/cncr.22059
pubmed: 16826584
Dutta R, Abdelhalim A, Martin JW et al (2016) Effect of tumor location on survival in urinary bladder adenocarcinoma: a population-based analysis. Urol Oncol Semin Orig Investig 34:531.e1–531.e6. https://doi.org/10.1016/j.urolonc.2016.06.009
doi: 10.1016/j.urolonc.2016.06.009
Dandekar NP, Dalal AV, Tongaonkar HB, Kamat MR (1997) Adenocarcinoma of bladder. Eur J Surg Oncol 23:157–160. https://doi.org/10.1016/S0748-7983(97)80012-1
doi: 10.1016/S0748-7983(97)80012-1
pubmed: 9158192
Cho SY, Moon KC, Park JH et al (2013) Outcomes of Korean patients with clinically localized urachal or non-urachal adenocarcinoma of the bladder. Urol Oncol Semin Orig Investig 31:24–31. https://doi.org/10.1016/j.urolonc.2010.10.002
doi: 10.1016/j.urolonc.2010.10.002
Grignon DJ, Ro JY, Ayala AG et al (1991) Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases. Cancer. https://doi.org/10.1002/1097-0142(19910415)67:8%3c2165:AID-CNCR2820670827%3e3.0.CO;2-M
doi: 10.1002/1097-0142(19910415)67:8%3c2165::AID-CNCR2820670827%3e3.0.CO;2-M
pubmed: 1706216
Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. https://doi.org/10.1080/00273171.2011.568786
doi: 10.1080/00273171.2011.568786
Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF et al (2015) SEER cancer statistics review, 1975–2012. National Cancer Institute, Bethesda, MD
Edge SB, Compton CC (2010) The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471–1474
doi: 10.1245/s10434-010-0985-4
pubmed: 20180029
Dhillon J, Liang Y, Kamat AM et al (2015) Urachal carcinoma: a pathologic and clinical study of 46 cases. Hum Pathol 46:1808–1814. https://doi.org/10.1016/j.humpath.2015.07.021
doi: 10.1016/j.humpath.2015.07.021
pubmed: 26364859
pmcid: 4824311
Molina JR, Quevedo JF, Furth AF et al (2007) Predictors of survival from urachal cancer: a mayo clinic study of 49 cases. Cancer 110:2434–2440. https://doi.org/10.1002/cncr.23070
doi: 10.1002/cncr.23070
pubmed: 17932892
Collazo-Lorduy A, Castillo-Martin M, Wang L et al (2016) Urachal carcinoma shares genomic alterations with colorectal carcinoma and may respond to epidermal growth factor inhibition. Eur Urol 70:771–775. https://doi.org/10.1016/j.eururo.2016.04.037
doi: 10.1016/j.eururo.2016.04.037
pubmed: 27178450
pmcid: 5489411